Blog

SynbiCITE, the UK’s national centre for the commercialisation of synthetic biology, is powering the synthetic biology industry, applying lab-based R&D excellence to fuel the development of tools, products, processes and services for high-value manufacturing industries. SynbiCITE’s four-day MBA course exemplifies this, helping develop the entrepreneurial and management skills in scientists required to run a biotechnology […]

read more

Picture includes Tim Fell CEO at Synthace Oliver Sexton, Investment Director, and Pablo Lubroth, Investment Manager, UKI2S, share their thoughts on the recent SynbiTECH2019 conference in London. The global synthetic biology sector is growing rapidly; 2018 saw 98 synthetic biology companies raise a record $3.8 billion in venture capital, new IPOs, post-equity investments, and secondary market […]

read more

Innovative software company Synthace is working to transform the way that scientists and companies do biology. But they were helped in a critical transition in their business model by the UK Innovation & Science Seed Fund (UKI2S). London-based software company Synthace have a mission to transform the way scientists do biology. For the last century, […]

read more

1 2 3 6